FDA Approves Atezolizumab/Bevacizumab Combination for HCC
The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news